Special Drug Use Investigation for Relenza® (Zanamivir) (Prophylaxis)

GlaxoSmithKline622 enrolled

Overview

The purpose of this post-marketing surveillance study is to collect information on efficacy and safety for prophylactic administration of zanamivir in clinical practice in family or persons living with patients with influenza virus infection.

Study Type

OBSERVATIONAL

Enrollment

622

Conditions

Influenza, Human

Interventions

Zanamivir hydrateDRUG

Eligibility

Sex: ALL

Medical Language ↔ Plain English

Inclusion Criteria: * Subjects who meet the study population criteria Exclusion Criteria: * Subjects with a history of hypersensitivity to the ingredients of zanamivir

Outcomes

Primary Outcomes

The number of incidence of adverse events in subjects treated with zanamivir

Time frame: 11 days

Occurrence of influenza virus infection

Time frame: 11 days

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.